Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 01.04.2024 2 Am J Clin Oncol 2 Ann Surg Oncol 2 Ann Thorac Surg 3 Anticancer Res 1 Arch Pathol Lab Med 5 BMC Cancer 1 Br J Cancer 1 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Lett 2 Clin Exp Metastasis 1 Clin Lung Cancer 4 Eur J Cardiothorac Surg 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 2 J Clin Oncol 1 J Comput Assist Tomogr 1 JAMA Oncol 1 Lancet Oncol 2 Lung Cancer 2 Oncologist 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. 
   Pretreatment Characteristics of Carcinoid Tumors of the Lung Which Predict Aggressive Behavior: Erratum.
   Am J Clin Oncol. 2024;47:e1.
   PubMed        
   
   
2. LIU X, Shen Q, Wen Y, Jiang Z, et al
   Diagnosis of Malignant Pulmonary Nodules Using a Combination of Tumor-associated Autoantibodies and Computed Tomography.
   Am J Clin Oncol. 2024;47:149-154.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. YAN HJ, Zhao JS, Zuo HD, Zhang JJ, et al
   Dual-Region Computed Tomography Radiomics-Based Machine Learning Predicts Subcarinal Lymph Node Metastasis in Patients with Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2024 Mar 23. doi: 10.1245/s10434-024-15197.
   PubMed         Abstract available
   
   
4. LIU J, Shi Z, Cao B, Wang Z, et al
   Prognostic Significance of the Highest Mediastinal Lymph Node Involvement in Patients with Stage III-N2 Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2024 Mar 23. doi: 10.1245/s10434-024-15184.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. BLASBERG JD, Li A
   Evening the Odds: Making 1 + 1 = 2 for Bilobectomy.
   Ann Thorac Surg. 2024;117:874-875.
   PubMed        
   
   
6. KAMIGAICHI A, Mimae T, Tsubokawa N, Miyata Y, et al
   Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.
   Ann Thorac Surg. 2024;117:743-751.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. MAEZAWA Y, Taguchi M, Kawakami T, Inui T, et al
   Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study.
   Anticancer Res. 2024;44:1751-1757.
   PubMed         Abstract available
   
   
8. CHIU KL, Wang SC, Li CH, Shen TC, et al
   The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51 Genotypes to Lung Cancer in Taiwan.
   Anticancer Res. 2024;44:1409-1416.
   PubMed         Abstract available
   
   
9. HASHIMOTO K, Kaira K, Imai H, Miura YU, et al
   Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
   Anticancer Res. 2024;44:1541-1551.
   PubMed         Abstract available
   
   

   
   Arch Pathol Lab Med

10. MILLER LJ, Holmes IM, Lew M
    An Updated Contextual Approach to Mesothelial Proliferations in Pleural Effusion Cytology Leveraging Morphology, Ancillary Studies, and Novel Biomarkers.
    Arch Pathol Lab Med. 2024;148:409-418.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. QI H, Hou Y, Zheng Z, Zheng M, et al
    Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    BMC Cancer. 2024;24:362.
    PubMed         Abstract available
    
    
12. LI LX, Socinski MA, Kichenadasse G, Karapetis CS, et al
    A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
    BMC Cancer. 2024;24:379.
    PubMed         Abstract available
    
    
13. XIE M, Gao J, Ma X, Song J, et al
    The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
    BMC Cancer. 2024;24:372.
    PubMed         Abstract available
    
    
14. ELBASHEER MMA, Bohrmann B, Chen Y, Lv J, et al
    Reproductive factors and risk of lung cancer among 300,000 Chinese female never-smokers: evidence from the China Kadoorie Biobank study.
    BMC Cancer. 2024;24:384.
    PubMed         Abstract available
    
    
15. WEI Q, Deng T, Wu J, Zeng H, et al
    Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
    BMC Cancer. 2024;24:393.
    PubMed         Abstract available
    
    

    
    Br J Cancer

16. HARATANI K, Nakamura A, Mamesaya N, Sawa K, et al
    Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662.
    PubMed         Abstract available
    
    

    
    Cancer

17. VITA E, Monaca F, Milardi D, Mastrantoni L, et al
    Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
    Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

18. HUO H, Feng Y, Tang Q
    Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Cancer Chemother Pharmacol. 2024 Mar 26. doi: 10.1007/s00280-024-04646.
    PubMed        
    
    

    
    Cancer Lett

19. MORIMOTO K, Yamada T, Hirai S, Katayama Y, et al
    AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
    Cancer Lett. 2024;587:216692.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

20. HAIDER MT, Freytag V, Krause L, Spethmann T, et al
    Comparison of ex vivo bioluminescence imaging, Alu-qPCR and histology for the quantification of spontaneous lung and bone metastases in subcutaneous xenograft mouse models.
    Clin Exp Metastasis. 2024;41:103-115.
    PubMed         Abstract available
    
    
21. POURJAMAL N, Yazdi N, Halme A, Joncour VL, et al
    Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Clin Exp Metastasis. 2024 Feb 17. doi: 10.1007/s10585-024-10278.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

22. NOURMOHAMMADI N, Liang THP, Sadigh G
    Patient-Provider Lung Cancer Screening Discussions: An Analysis of a National Survey.
    Clin Lung Cancer. 2024 Mar 2:S1525-7304(24)00034.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

23. WANG S, Bao X, Yang F, Shi H, et al
    Multiparametric evaluation of mediastinal lymph node metastases in clinical T0-T1c stage non-small-cell lung cancers.
    Eur J Cardiothorac Surg. 2024;65:ezae059.
    PubMed         Abstract available
    
    
24. MCALLISTER MA, Rochefort MM, Ugalde Figueroa P, Leo R, et al
    Complete anatomic segmentectomy shows improved oncologic outcomes compared to incomplete anatomic segmentectomy.
    Eur J Cardiothorac Surg. 2024;65:ezae089.
    PubMed         Abstract available
    
    
25. BACIEWICZ FA JR
    'The Nodes Always Know'!
    Eur J Cardiothorac Surg. 2024;65:ezae102.
    PubMed        
    
    
26. TIAN Y, Liu Z, Pan H, Zhu H, et al
    Perioperative immune checkpoint blockades improve prognosis of resectable non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2024 Mar 26:ezae110. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

27. WALLS GM, Mistry H, Barlesi F, Bezjak A, et al
    Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small-cell lung cancer: a brief report from the CONVERT trial.
    Int J Radiat Oncol Biol Phys. 2024 Mar 11:S0360-3016(24)00382.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

28. JIANG L, Yang P, Liu Y, Li J, et al
    BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    J Cancer Res Clin Oncol. 2024;150:162.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

29. KATHURIA H, Wiener RS
    Toward Racial Equity in Lung Cancer Screening Eligibility.
    J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351.
    PubMed        
    
    
30. POTTER AL, Xu NN, Senthil P, Srinivasan D, et al
    Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
    J Clin Oncol. 2024 Mar 27:JCO2301780. doi: 10.1200/JCO.23.01780.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

31. MAGNINI A, Lorini C, Calistri L, Calcagni F, et al
    The Impact of Rapid On-site Evaluation on Diagnostic Performance of Computed Tomography-Guided Core Needle Biopsy in Lung Cancer.
    J Comput Assist Tomogr. 2024 Mar 22. doi: 10.1097/RCT.0000000000001606.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

32. ITO K, Suzuki Y, Sakaguchi T, Fujiwara K, et al
    Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0023.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

33. SMIT EF, Felip E, Uprety D, Nagasaka M, et al
    Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Lancet Oncol. 2024;25:439-454.
    PubMed         Abstract available
    
    

    
    Lung Cancer

34. RODRIGUEZ J
    On the Hispanic paradox in lung cancer.
    Lung Cancer. 2024;190:107537.
    PubMed        
    
    
35. SUN M, Feng Q, Yan Q, Zhao H, et al
    Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer.
    Lung Cancer. 2024;190:107541.
    PubMed         Abstract available
    
    

    
    Oncologist

36. XU Y, Ji H, Zhang Y, Xiong L, et al
    Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2024 Mar 25:oyae052. doi: 10.1093.
    PubMed         Abstract available
    
    
37. PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al
    Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
    Oncologist. 2024 Mar 23:oyae043. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

38. LI Q, Wei Z, Zhang Y, Zheng C, et al
    Causal role of metabolites in non-small cell lung cancer: Mendelian randomization (MR) study.
    PLoS One. 2024;19:e0300904.
    PubMed         Abstract available
    
    
39. MOMOKI Y, Ichinose A, Nakamura K, Iwano S, et al
    Development of automatic generation system for lung nodule finding descriptions.
    PLoS One. 2024;19:e0300325.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.